Tetanus-diphtheria-acellular Pertussis (Tdap)

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
GC3111BPhase 1/21 trial
Active Trials
NCT06997627RecruitingEst. May 2026

Trial Timeline

Clinical trial activity over time

2025
2026
GC BiopharmaGC3111B

Clinical Trials (1)

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Start: Jun 2025Est. completion: May 2026
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space